Michael D. Howell, PhD

President & Chief Executive Officer
Mountaineer Biosciences, Inc

Biography

Dr. Michael Howell is an immunologist with more than 25 years of experience in research and development.  He currently serves as the President and CEO of Mountaineer Biosciences, Inc, and Co-Founder of Galileo Biosystems.  Additionally, he serves as a scientific advisor to several startup biotechnology companies and investment companies.

Dr. Howell began his career as a faculty member at National Jewish Health, and held roles of increasing responsibility at Boehringer Ingelheim, Immune Tolerance Network, MedImmune/AstraZeneca, Incyte Corporation, DermTech, and ZuraBio. Throughout his career, Dr. Howell has led research and development teams dedicated to the discovery of novel therapies and the integration of precision and personalized medicine approaches into clinical development.  His efforts have led to the approval of multiple therapies including Opzelura (ruxolitinib), Jakafi (ruxolitinib), Adbry/Adtralza (tralokinumab), Tezpire (tezepelumab), Spevigo (spesolimab), and others; novel diagnostic approaches to patient treatment, and have been highlighted in more than 65 peer peer-reviewed publications and reviews on immunologic mechanisms and has led to recent patent applications for therapeutic interventions and biomarker strategies in inflammatory diseases.

Dr. Howell received his PhD in Immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health.